Faraday Pharmaceuticals, Inc. — Form D
Faraday Pharmaceuticals, Inc. of SEATTLE, WA, a company, filed a Form D exempt-offering notice with the SEC on 2022-11-07. The offering totals $102.8M, of which $52.8M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2022-11-07
- Form: D
- Accession: 0001614107-22-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $102.8M
- Amount sold: $52.8M
- Remaining: $50.0M
- Investors: 3
- Date of first sale: 2022-10-24
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-464006
Issuer
- Name: Faraday Pharmaceuticals, Inc.
- CIK: 0001614107
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2013
- Address: 1616 EASTLAKE AVENUE E., SEATTLE, WA, 98102
- Phone: 206-492-5310
Officers, directors & promoters (17)
| Name | Role | Location |
|---|
| Steven Gillis | Director | South San Francisco, CA |
| Lawrence Gozlan | Director | Fort Collins, CO |
| Stephen Hill | Director | Lake Forest, IL |
| Terrance McGuire | Director | Cambridge, MA |
| Mark Roth | Director | Seattle, WA |
| Brian Blackman | Executive Officer | Seattle, WA |
| Stephen Hill | Executive Officer | Lake Forest, IL |
| Ronald Kierpa | Executive Officer | Seattle, WA |
| Patrick Rock | Executive Officer | Seattle, WA |
| Simon Tulloch | Executive Officer | Seattle, WA |
| Mark Roth | Promoter | Seattle, WA |
| Steven Gillis | Executive Officer | South San Francisco, CA |
| Steven Gillis | Promoter | South San Francisco, CA |
| Thomas King | Director | Brooklyn, NY |
| Paulina Hill | Director | Cambridge, MA |
| Robert Nelsen | Director | Seattle, WA |
| Mark Roth | Executive Officer | Seattle, WA |
Other filings by this issuer (4)
More